ScreenerHero

HYFT MindWalk Holdings Corp.

NAS · US · Healthcare · Biotechnology · mindwalkai.com
1.500USD-3.23%Mkt Cap: 70.67M $P/E: —

MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ te…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap70.67M USD
Enterprise Value68.88M USD
Revenue (TTM)16.23M USD
Gross Profit9.15M USD
Net Income (TTM)-13.95M USD
Revenue/Share0.35 USD
Last Price1.500 USD
Fiscal Year EndApr 2026
MR QuarterJul 2026
Employees74
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-4.28
EV/Revenue4.24
P/S4.50
P/B15.02
EPS (TTM)-0.26
EPS (Forward)—
52W Range
0.990026% of range2.990
52W High2.990 USD
52W Low0.9900 USD
Profitability
Gross Margin58.80%
Oper. Margin-159.86%
EBITDA Margin-99.17%
Profit Margin-89.66%
ROE-118.72%
ROA-65.26%
Growth
Revenue Growth21.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.46M USD
CapEx (TTM)398.00K USD
FCF Margin54.06%
FCF Yield12.42%
Net Debt-4.14M USD
Net Debt/EBITDA0.26
Balance Sheet
Debt/Equity0.30
Current Ratio1.84
Quick Ratio1.63
Book Value/Sh0.10 USD
Cash/Share0.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 23, 2020
Splits
Last Split1:5
Split DateNov 23, 2020
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.333 USD
Upside (mean)+188.9%
Target Range3.000 USD – 5.000 USD
3.000+188.9% to mean5.000
# Analysts3
Ownership
Shares Out.47.11M
Float42.75M
Insiders9.14%
Institutions9.29%
Short Interest
Short Ratio5.5d
Short % Float1.57%
Short % Out.1.55%
Shares Short730.16K
Short (prev mo.)713.28K
Technical
SMA 501.352 (+10.9%)
SMA 2001.468 (+2.2%)
Beta0.78
S&P 52W Chg16.45%
Avg Vol (30d)227.82K
Avg Vol (10d)169.18K
Technical Indicators
RSI (14)57.6
MACD0.0270
MACD Signal0.0079
MACD Hist.+0.0191
BB Upper1.552 USD
BB Middle1.372 USD
BB Lower1.193 USD
BB Width26.18%
ATR (14)0.1143 USD
Vol Ratio (20d)1.13x